Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts

  • Authors:
    • Miguel Muñoz
    • Michael Berger
    • Marisa Rosso
    • Ana Gonzalez-Ortega
    • Andrés Carranza
    • Rafael Coveñas
  • View Affiliations

  • Published online on: November 5, 2013     https://doi.org/10.3892/ijo.2013.2164
  • Pages: 137-146
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma is a highly malignant bone tumor in children and adolescents. Aprepitant is a selective high‑affinity antagonist of the human neurokinin‑1 (NK‑1) receptor (NK1R) with robust antitumor activity. No data exist on the presence of NK1R in osteosarcoma and whether this tumor responds to NK1R antagonists. Here, we analyzed the expression of NK1R in the human osteosarcoma cell line MG-63 with western blot analysis and PCR and found significant expression both at the protein and mRNA levels. We further studied the growth inhibitory capacity of aprepitant and other NK1R antagonists on MG-63 in vitro using an MTS cytotoxicity assay and DAPI staining. All antagonists induced tumor growth inhibition and apoptosis. Synergism was observed for the combination of L-733,060 with common cytostatic drugs in MG-63, but not in non-malignant HEK293 cells. Pretreatment of HEK293 with L-733,060 prior to exposure to cytostatic drugs partially protected HEK293 cells from inhibition by these drugs. Furthermore, nanomolar concentrations of substance P (SP), the natural ligand of the NK1R, increased the growth rate of MG‑63 cells and micromolar concentrations of aprepitant inhibited SP-induced growth in a dose‑dependent manner. In vivo, a xenograft for MG-63 was created in nude mice and treated with peritumoral s.c. injections of fosaprepitant, which resulted in a significant reduction of tumor volume. Collectively, we demonstrated for the first time that the NK1R is expressed in human osteosarcoma cell line MG‑63 and that this receptor can be targeted with NK1R antagonists both in vitro as well as in vivo.
View Figures
View References

Related Articles

Journal Cover

2014-January
Volume 44 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

The Cancer Story
Copy and paste a formatted citation
x
Spandidos Publications style
Muñoz M, Berger M, Rosso M, Gonzalez-Ortega A, Carranza A and Coveñas R: Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. Int J Oncol 44: 137-146, 2014
APA
Muñoz, M., Berger, M., Rosso, M., Gonzalez-Ortega, A., Carranza, A., & Coveñas, R. (2014). Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. International Journal of Oncology, 44, 137-146. https://doi.org/10.3892/ijo.2013.2164
MLA
Muñoz, M., Berger, M., Rosso, M., Gonzalez-Ortega, A., Carranza, A., Coveñas, R."Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts". International Journal of Oncology 44.1 (2014): 137-146.
Chicago
Muñoz, M., Berger, M., Rosso, M., Gonzalez-Ortega, A., Carranza, A., Coveñas, R."Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts". International Journal of Oncology 44, no. 1 (2014): 137-146. https://doi.org/10.3892/ijo.2013.2164